Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates

Drug-combination nanoparticles (DcNPs) administered subcutaneously represent a potential long-acting lymphatic-targeting treatment for HIV infection. The DcNP containing lopinavir (LPV)-ritonavir (RTV)-tenofovir (TFV), Targeted-Long-Acting-Antiretroviral-Therapy product candidate 101 (TLC-ART 101),...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Pharm Sci
Autores principales: Perazzolo, Simone, Shireman, Laura M., Koehn, Josefin, McConnachie, Lisa A., Kraft, John C., Shen, Danny D., Ho, Rodney J.Y.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553477/
https://ncbi.nlm.nih.gov/pubmed/30121315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2018.07.032
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares